News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

May 7, 2024

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 5 June 2024 at 09.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan 8 in Stockholm. Registration starts at 08.30 CEST. NOTE: This is an unofficial translation of…

June 2, 2022

Bulletin from the annual general meeting of Lipidor AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor AB (publ) (“the Company”) on 2 June. The…

May 20, 2022

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have…

May 5, 2022

Lipidor AB (publ) publishes interim report for first quarter 2022

STOCKHOLM, Sweden, 5 May 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…

May 3, 2022

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 3[rd] May 2022: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice…

April 28, 2022

Lipidor AB (publ) publishes annual report for 2021

STOCKHOLM, Sweden, 28th April 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the…

March 25, 2022

Lipidor strengthens its operational team and recruits Supply Chain & Operations Manager

STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened…

February 23, 2022

Lipidor AB (publ) publishes year-end report for 2021

STOCKHOLM, Sweden, 23 February 2022 – Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2021.

January 26, 2022

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

STOCKHOLM, Sweden, 26[th] January 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have…

December 17, 2021

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, 17[th] December 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for…

December 9, 2021

Lipidor presents Nomination Committee

STOCKHOLM, 9[th] December 2021 – In accordance with the current nomination committee instructions for Lipidor AB (publ) (Nasdaq First North Growth Market:…